<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270069" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39950188</article-id><article-id pub-id-type="pmc">PMC11822360</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70069</article-id><article-id pub-id-type="publisher-id">DEO270069</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Feasibility of a novel self&#x02010;assembling submucosal injection peptide solution for endoscopic mucosal resection of colorectal lesions: A multicenter study</article-title><alt-title alt-title-type="left-running-head">SATO <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270069-cr-0001" contrib-type="author"><name><surname>Sato</surname><given-names>Keigo</given-names></name><xref rid="deo270069-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270069-cr-0002" contrib-type="author"><name><surname>Fukuchi</surname><given-names>Takehide</given-names></name><xref rid="deo270069-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270069-cr-0003" contrib-type="author"><name><surname>Kondo</surname><given-names>Shinpei</given-names></name><xref rid="deo270069-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270069-cr-0004" contrib-type="author"><name><surname>Nakano</surname><given-names>Yuya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4154-5467</contrib-id><xref rid="deo270069-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270069-cr-0005" contrib-type="author"><name><surname>Hachisu</surname><given-names>Yoko</given-names></name><xref rid="deo270069-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270069-cr-0006" contrib-type="author"><name><surname>Kasuga</surname><given-names>Kengo</given-names></name><xref rid="deo270069-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270069-cr-0007" contrib-type="author"><name><surname>Matsui</surname><given-names>Ayako</given-names></name><xref rid="deo270069-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270069-cr-0008" contrib-type="author"><name><surname>Aoki</surname><given-names>Hironori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0070-4900</contrib-id><xref rid="deo270069-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="deo270069-cr-0009" contrib-type="author"><name><surname>Takizawa</surname><given-names>Kohei</given-names></name><xref rid="deo270069-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="deo270069-cr-0010" contrib-type="author"><name><surname>Kuribayashi</surname><given-names>Shiko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5067-552X</contrib-id><xref rid="deo270069-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270069-cr-0011" contrib-type="author"><name><surname>Takeuchi</surname><given-names>Yoji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3814-298X</contrib-id><xref rid="deo270069-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270069-cr-0012" contrib-type="author" corresp="yes"><name><surname>Uraoka</surname><given-names>Toshio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4425-4331</contrib-id><xref rid="deo270069-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>uraoka@gunma-u.ac.jp</email><email>toshi_urao@yahoo.co.jp</email></address></contrib></contrib-group><aff id="deo270069-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Gunma University Graduate School of Medicine</institution>
<named-content content-type="country-part">Gunma</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270069-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Fujisawa City Hospital</institution>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270069-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Gunma Saiseikai Maebashi Hospital</institution>
<named-content content-type="country-part">Gunma</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270069-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Isesaki Municipal Hospital</institution>
<named-content content-type="country-part">Gunma</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270069-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Endoscopy Center</named-content>
<institution>Koyukai Shin&#x02010;Sapporo Hospital</institution>
<named-content content-type="country-part">Hokkaido</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Toshio Uraoka, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3&#x02010;39&#x02010;22 Showa&#x02010;machi, Maebashi 371&#x02013;8514, Japan.<break/> Email: <email>uraoka@gunma-u.ac.jp</email>; <email>toshi_urao@yahoo.co.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="18">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70069</elocation-id><history>
<date date-type="rev-recd"><day>06</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>16</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70069.pdf"/><abstract><title>Abstract</title><sec id="deo270069-sec-0010"><title>Objectives</title><p>Although a novel submucosal injection material consisting of a fully synthetic, self&#x02010;assembling peptide solution, PuraLift, has recently become commercially available in Japan, there are a few reports regarding the usefulness of this solution. The aim of this study was to investigate the feasibility of PuraLift for conventional endoscopic mucosal resection (EMR) in clinical practice.</p></sec><sec id="deo270069-sec-0020"><title>Methods</title><p>This multicenter retrospective study was conducted at the endoscopy units of five institutions from January 2023 to May 2023. Consecutive patients who underwent EMR with PuraLift for 5&#x02013;20&#x02010;mm colorectal lesions were included in the introduction of this solution at each institute. The primary endpoint was the &#x0201c;effective resection&#x0201d; rate, defined as pathological complete resection, with &#x0201c;effective injection&#x0201d; defined as requiring no more than one additional injection due to adequate maintenance of mucosal lifting during EMR.</p></sec><sec id="deo270069-sec-0030"><title>Results</title><p>In total, 110 lesions in 70 patients were treated by conventional EMR using PuraLift. En&#x02010;bloc resection was performed for 109 (99%) lesions, and complete resection was performed for 102 (93%) lesions. More than 95% of the lesions were neoplastic. Additional injections were required in only two lesions. Both were single additional injections, and the median overall injection volume was 1.5 mL. Therefore, the effective injection rate was 93% (95% confidence interval, 86%&#x02013;96%). No adverse events occurred during the study period.</p></sec><sec id="deo270069-sec-0040"><title>Conclusions</title><p>Although direct comparison with other materials is required, PuraLift seems feasible as an injection material for EMR.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270069-kwd-0001">colon</kwd><kwd id="deo270069-kwd-0002">colonoscopy</kwd><kwd id="deo270069-kwd-0003">colorectal polyps</kwd><kwd id="deo270069-kwd-0004">endoscopic mucosal resection</kwd><kwd id="deo270069-kwd-0005">endoscopic resection</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="5"/><page-count count="8"/><word-count count="3886"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270069-sec-0050"><title>INTRODUCTION</title><p>Endoscopic resection is one of the least invasive treatment options for precancerous lesions or early&#x02010;stage cancer without a risk of lymph node metastasis. However, residual polyps after incomplete endoscopic resection can lead to post&#x02010;colonoscopy colorectal cancer. Therefore, endoscopists have made various efforts to achieve complete local resection. Recently, cold snare polypectomy, a polypectomy procedure without electrocautery, has been performed for adenomas smaller than 10 mm. However, for lesions larger than 10 mm or those suspected to be malignant, endoscopic mucosal resection (EMR) is commonly performed.</p><p>EMR involves the injection of fluid into the submucosal layer to elevate the lesion into a polyp&#x02010;like shape, followed by snaring and resection with an electrosurgical snare. This technique improves the complete resection rate of colorectal lesions smaller than 20 mm. The submucosal injection also reduces the risk of perforation, a serious adverse event in endoscopic resection, by increasing the distance between the muscle layer and the mucosa. Several agents have been used as local injection solutions, and the search for the most effective solution continues.<xref rid="deo270069-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270069-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>PuraLift (3&#x02010;D Matrix; Tokyo), a novel submucosal injection material consisting of a fully synthetic and self&#x02010;assembling peptide solution, was recently approved under the Japanese public insurance reimbursement system. Animal studies have shown its usefulness as a submucosal injection material for EMR.<xref rid="deo270069-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> We subsequently published a case report showing that PuraLift provided sufficient protrusion formation for safe endoscopic submucosal dissection.<xref rid="deo270069-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The present multicenter retrospective study was performed to investigate the feasibility of PuraLift as an injection material for conventional EMR in clinical practice.</p></sec><sec id="deo270069-sec-0060"><title>METHODS</title><sec id="deo270069-sec-0070"><title>Study design and patients</title><p>This retrospective multicenter observational study was conducted at the endoscopy units of five centers (Gunma University Graduate School of Medicine, Fujisawa City Hospital, Gunma Saiseikai Maebashi Hospital, Isesaki Municipal Hospital, and Koyukai Shin&#x02010;Sapporo Hospital) from January 2023 to May 2023, shortly after approval of PuraLift by the Japanese public insurance reimbursement system on December 1, 2022. The data of consecutive patients who underwent EMR after injection of PuraLift for colorectal lesions between the introduction of this solution at each institute and May 31 were collected and analyzed. During the study period, endoscopists were recommended to use PuraLift for 5&#x02010; to 10&#x02010;mm non&#x02010;pedunculated lesions suspected to be high&#x02010;grade dysplasia or cancer, pedunculated lesions, or 10&#x02010; to 20&#x02010;mm lesions not suitable for cold snare polypectomy. Patients with recurrent lesions, ulcers in the lesions, inflammatory bowel disease, familial adenomatous polyposis, undergoing chemotherapy, and deemed unsuitable for use of PuraLift by the treating endoscopists at each institution underwent conventional EMR using 0.9% saline, glycerol, hyaluronate sodium,<xref rid="deo270069-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> or endoscopic submucosal dissection.</p><p>The study protocol was approved by the Gunma University Hospital Clinical Research Review Board. All patients provided written informed consent to undergo EMR. Informed consent for participating in this study was obtained in the form of an opt&#x02010;out method on the website. The reporting of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology Statement.<xref rid="deo270069-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p></sec><sec id="deo270069-sec-0080"><title>Injection material</title><p>The injection material used in this study, PuraLift, is an aqueous peptide solution in a vial, primarily composed of self&#x02010;assembling peptides at physiologic pH. When placed under physiological conditions, the peptide solution quickly forms a hydrogel comprising a network of nanofibers through contact with body fluids such as digestive and tissue fluids secreted from the stomach and intestines. The injected hydrogel remains in the submucosa, creating a wide separation between the mucosal and muscular layers. This results in the elevation of the lesion, which is maintained during EMR or endoscopic submucosal dissection.<xref rid="deo270069-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p></sec><sec id="deo270069-sec-0090"><title>Procedures</title><p>The endoscopic diagnoses of the lesions were based on their macroscopic appearance (Paris classification<xref rid="deo270069-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>), magnifying narrow&#x02010;band imaging findings (Japan Narrow&#x02010;band Imaging Expert Team [JNET] classification<xref rid="deo270069-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>), or pit pattern classification.<xref rid="deo270069-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270069-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> EMR was indicated for lesions with a JNET 2A/2B classification or a pit pattern other than V<sub>N</sub>, typically adenoma, sessile serrated lesion, and high&#x02010;grade dysplasia/intramucosal adenocarcinoma for 10&#x02010; to 20&#x02010;mm lesions.</p><p>EMR was performed according to each institution's protocol, primarily using carbon dioxide inflation. The use of a cap was left to the endoscopists&#x02019; discretion. After careful lesion assessment, PuraLift was injected to achieve adequate protrusion for EMR, allowing the lesion along with the surrounding non&#x02010;neoplastic mucosa to be entrapped by an electrosurgical snare. Adequate protrusion is generally considered as a bulge that is taller than 1 cm, has a steep rise, and has a vertical rise that is longer than its horizontal extent (Figure&#x000a0;<xref rid="deo270069-fig-0001" ref-type="fig">1</xref>). All endoscopists attempted R0 resection during the initial resection. Multiple needle punctures without insertion and withdrawal of the endoscopic needle through the endoscope working channel were performed in one session. Additional injections were permitted and counted if the appropriate protrusion was not maintained or had shrunk after the initial injection session. After the submucosal injection of PuraLift, the mucosal protrusion, including the lesion, was entrapped with an electrosurgical snare. Electrocautery was then applied to remove the lesion. If residual lesions were observed or suspected, additional injection and resection using the same strategy were allowed until complete removal was achieved. The electrosurgical snares used in this study were chosen based on their availability in each institution. Although the electrocautery settings differ due to the different equipment and electrosurgical unit used at each facility, the main facility, Gunma University, used the end&#x02010;cut mode Effect2 40W (VIO3; Erbe Elektromedizin GmbH) for EMR, and the other facilities had similar settings.</p><fig position="float" fig-type="FIGURE" id="deo270069-fig-0001"><label>FIGURE 1</label><caption><p>Lesion underwent endoscopic mucosal resection after injection of PuraLift.</p></caption><graphic xlink:href="DEO2-5-e70069-g001" position="anchor" id="jats-graphic-1"/></fig><p>The resected specimens were retrieved, fixed in 10% formalin solution, and embedded in paraffin. The fixed specimens were sectioned serially at 2&#x02010;mm intervals. Histological diagnoses and assessments of resection margins were made according to the Japanese Classification of Colorectal Carcinoma.<xref rid="deo270069-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p></sec><sec id="deo270069-sec-0100"><title>Data collection</title><p>We collected the following data from the patients&#x02019; medical records and compiled it at Gunma University Graduate School of Medicine: age, sex, lesion location, macroscopic classification,<xref rid="deo270069-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> lesion size, colonoscopy experience, pathological diagnosis including evaluation of lesion involvement on the margins, number of additional injections, necessity for other injection materials, and intraoperative and postoperative adverse events. Postoperative adverse events were generally reported at an outpatient visit two weeks after treatment to explain the pathology results and any adverse events were interviewed and recorded on the medical chart.</p></sec><sec id="deo270069-sec-0110"><title>Endpoints and research data</title><p>The primary endpoint was the &#x0201c;effective resection&#x0201d; rate, defined as pathological complete resection, with &#x0201c;effective injection&#x0201d; defined as requiring no more than one additional injection due to adequate maintenance of mucosal lifting during EMR. Additional injection was defined as any injections performed after the initial injection to achieve sufficient elevation. The secondary outcome measures were the en bloc resection rate, number of additional injections, use of other injection material, and adverse events.</p><p>Because PuraLift was used for lesions in which cold snare polypectomy was not indicated, some of the enrolled patients had pedunculated lesions. For most pedunculated lesions, however, en bloc or complete resection was not difficult to achieve regardless of submucosal injection, and we analyzed outcomes only for non&#x02010;pedunculated lesions in a subgroup analysis.</p></sec><sec id="deo270069-sec-0120"><title>Sample size calculation</title><p>A performance goal was established based on a previous clinical study<xref rid="deo270069-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> involving a 0.13% hyaluronic acid solution, a similar high&#x02010;viscosity injection material for colorectal EMR. In that study, the usefulness rate for assisted endoscopic resection was 81.6% (31/38), with a 95% confidence interval (CI) ranging from 65.7% to 92.3%. To estimate this usefulness rate with higher precision, the lower limit of the 95% CI was set as the goal to exceed 70%, and the number of cases needed to achieve this goal was calculated to be 62. This was a retrospective observational study, and as many cases as possible were accumulated during the study period, exceeding the calculated sample size.</p></sec><sec id="deo270069-sec-0130"><title>Statistical analysis</title><p>Categorical variables are presented as point estimates with 95% CIs. Quantitative data with a normal distribution are presented as mean (standard deviation). Non&#x02010;parametric data are presented as median (range).</p></sec></sec><sec id="deo270069-sec-0140"><title>RESULTS</title><sec id="deo270069-sec-0150"><title>Patient and lesion characteristics</title><p>During the study period, a total of 358 lesions in 208 patients were treated by conventional EMR. After excluding lesions and patients where injection solutions other than PuraLift were used, 110 lesions in 70 patients were treated by conventional EMR using PuraLift (Figure&#x000a0;<xref rid="deo270069-fig-0002" ref-type="fig">2</xref>). All data were collected and analyzed at Gunma University. The characteristics of the patients and lesions are shown in Table&#x000a0;<xref rid="deo270069-tbl-0001" ref-type="table">1</xref>. The patients&#x02019; median age was 67 years, and 61% were male. The lesions were most frequently located in the left&#x02010;sided colon, and protruded lesions were more common than superficial lesions (72% vs. 26%, respectively). Approximately one&#x02010;third of the lesions were&#x000a0;&#x0003e;11 mm, and 36% of the lesions were resected by less experienced endoscopists (&#x0003c;1000 colonoscopy procedures).</p><fig position="float" fig-type="FIGURE" id="deo270069-fig-0002"><label>FIGURE 2</label><caption><p>Study flowchart of the enrolled lesions.</p></caption><graphic xlink:href="DEO2-5-e70069-g002" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="deo270069-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient and lesion characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Patients</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 70</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">67 (38&#x02013;86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">43 (61.4)</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Lesions</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 110</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Location</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right colon</td><td align="char" rowspan="1" colspan="1">44 (40.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Left colon</td><td align="char" rowspan="1" colspan="1">51 (46.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">15 (13.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Morphology</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;Ip</td><td align="char" rowspan="1" colspan="1">19 (17.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;Is</td><td align="char" rowspan="1" colspan="1">62 (56.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;IIa</td><td align="char" rowspan="1" colspan="1">29 (26.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Size</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">5&#x02013;10 mm</td><td align="char" rowspan="1" colspan="1">73 (63.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">11&#x02013;15 mm</td><td align="char" rowspan="1" colspan="1">30 (27.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">16&#x02013;20 mm</td><td align="char" rowspan="1" colspan="1">7 (6.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Experience, number of procedures</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;1000</td><td align="char" rowspan="1" colspan="1">40 (36.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1000&#x02013;2000</td><td align="char" rowspan="1" colspan="1">22 (20.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2001&#x02013;5000</td><td align="char" rowspan="1" colspan="1">23 (20.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003e;5000</td><td align="char" rowspan="1" colspan="1">25 (22.7)</td></tr></tbody></table><table-wrap-foot><fn id="deo270069-tbl1-note-0001"><p>Data are presented as <italic toggle="yes">n</italic> (%) or median (range).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270069-sec-0160"><title>Measured outcomes</title><p>Table&#x000a0;<xref rid="deo270069-tbl-0002" ref-type="table">2</xref> shows the treatment outcomes in this study. En&#x02010;bloc resection was performed for 109 (99%) lesions, and complete resection was performed for 102 (93%) lesions. More than 95% of the lesions were neoplastic. Additional injections were required for only two lesions. Both were single additional injections, and the median overall injection volume was 1.5 mL. No additional injection fluid was used other than PuraLift. Therefore, the effective resection rate was 93% (95% CI, 86&#x02013;96). There were no adverse events related to this agent or the EMR procedure.</p><table-wrap position="float" id="deo270069-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Treatment outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Lesions</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 110 [95% confidence interval] (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of additional injections</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">108 (98.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">2 (1.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total injection amount, mL</td><td align="char" rowspan="1" colspan="1">1.5 (0.2&#x02013;14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other injection material</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="char" rowspan="1" colspan="1">110 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">109 (99.1 [94.5&#x02013;100])</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">102 (92.7 [86.1&#x02013;96.5])</td></tr><tr><td align="left" rowspan="1" colspan="1">Effective resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">102 (92.7 [86.1&#x02013;96.5])</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathological diagnosis</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Adenoma</td><td align="char" rowspan="1" colspan="1">93 (84.6)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="char" rowspan="1" colspan="1">10 (9.1)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Intramucosal adenocarcinoma</td><td align="char" rowspan="1" colspan="1">8 (7.2)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Submucosal adenocarcinoma</td><td align="char" rowspan="1" colspan="1">2 (1.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hyperplasia</td><td align="char" rowspan="1" colspan="1">3 (2.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Sessile serrated lesion</td><td align="char" rowspan="1" colspan="1">3 (2.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Inflammatory fibroid polyp</td><td align="char" rowspan="1" colspan="1">1 (0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events</td><td align="char" rowspan="1" colspan="1">0 (0 [0&#x02013;4.1])</td></tr></tbody></table><table-wrap-foot><fn id="deo270069-tbl2-note-0001"><p>Data are presented as <italic toggle="yes">n</italic> (%) or median (range).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270069-sec-0170"><title>Subgroup analysis for non&#x02010;pedunculated lesions</title><p>The characteristics of the patients and lesions, excluding pedunculated lesions, are shown in Table&#x000a0;<xref rid="deo270069-tbl-0003" ref-type="table">3</xref>. Age, sex, and lesion location tended to be similar to those of the overall participants. Almost three&#x02010;fourths of the lesions were 5&#x02013;10&#x02010;mm in size. One&#x02010;fourth of the lesions were resected by less experienced endoscopists (&#x0003c;1000 colonoscopy procedures).</p><table-wrap position="float" id="deo270069-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Patient and non&#x02010;pedunculated lesion characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Patients</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 91</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">68 (38&#x02013;86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">35 (61.4)</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Lesions</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 91</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Location</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right colon</td><td align="char" rowspan="1" colspan="1">40 (44.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Left colon</td><td align="char" rowspan="1" colspan="1">38 (41.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">13 (14.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Morphology</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;Is</td><td align="char" rowspan="1" colspan="1">62 (68.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;IIa</td><td align="char" rowspan="1" colspan="1">29 (31.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Size</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">5&#x02013;10 mm</td><td align="char" rowspan="1" colspan="1">66 (72.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">11&#x02013;15 mm</td><td align="char" rowspan="1" colspan="1">19 (20.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">16&#x02013;20 mm</td><td align="char" rowspan="1" colspan="1">6 (6.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Experience, number of procedures</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;1000</td><td align="char" rowspan="1" colspan="1">26 (28.6)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1000&#x02013;2000</td><td align="char" rowspan="1" colspan="1">21 (23.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2001&#x02013;5000</td><td align="char" rowspan="1" colspan="1">20 (22.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003e;5000</td><td align="char" rowspan="1" colspan="1">24 (26.4)</td></tr></tbody></table><table-wrap-foot><fn id="deo270069-tbl3-note-0001"><p>Data are presented as <italic toggle="yes">n</italic> (%) or median (range).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Table&#x000a0;<xref rid="deo270069-tbl-0004" ref-type="table">4</xref> shows the treatment outcomes excluding pedunculated lesions. The en bloc resection rate, complete resection rate, pathological diagnosis, additional injections, median injection volume, effective resection rate, and adverse events were similar to the overall results. The effective resection rate was 91% (95% CI, 83&#x02013;96) for non&#x02010;pedunculated lesions.</p><table-wrap position="float" id="deo270069-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Treatment outcomes for non&#x02010;pedunculated lesions.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Lesions</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;= 91 [95% confidence interval] (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of additional injections</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">89 (97.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total injection amount, mL</td><td align="char" rowspan="1" colspan="1">1.5 (0.2&#x02013;14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other injection material</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="char" rowspan="1" colspan="1">91 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">90 (99.0 [93.4&#x02013;100])</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">83 (91.2 [83.4&#x02013;95.7])</td></tr><tr><td align="left" rowspan="1" colspan="1">Effective resection</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">83 (91.2 [83.4&#x02013;95.7])</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathological diagnosis</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Adenoma</td><td align="char" rowspan="1" colspan="1">79 (86.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="char" rowspan="1" colspan="1">5 (5.5)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Intramucosal adenocarcinoma</td><td align="char" rowspan="1" colspan="1">3 (3.2)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Submucosal adenocarcinoma</td><td align="char" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hyperplasia</td><td align="char" rowspan="1" colspan="1">3 (2.73)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Sessile serrated lesion</td><td align="char" rowspan="1" colspan="1">3 (2.73)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Inflammatory fibroid polyp</td><td align="char" rowspan="1" colspan="1">1 (0.91)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events</td><td align="char" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn id="deo270069-tbl4-note-0001"><p>Data are presented as <italic toggle="yes">n</italic> (%) or median (range).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270069-sec-0180"><title>Subgroup analysis according to non&#x02010;pedunculated lesion size</title><p>Table&#x000a0;<xref rid="deo270069-tbl-0005" ref-type="table">5</xref> shows the results according to non&#x02010;pedunculated lesion size. EMR for 11&#x02013;20&#x02010;mm non&#x02010;pedunculated lesions was mainly performed by experienced endoscopists (&#x02265;1000 colonoscopy procedures). En&#x02010;bloc resection and complete resection of 5&#x02013;10&#x02010;mm lesions were performed in 66 of 66 (100%) cases and 62 of 66 (93.9%) cases, respectively. En&#x02010;bloc resection and complete resection of 11&#x02013;20&#x02010;mm lesions were performed in 24 of 25 (96%) and 21 of 25 (84%) cases, respectively. Adenocarcinoma was seen only in 11&#x02013;20&#x02010;mm lesions. Two additional counts of injection were performed in 11&#x02013;20&#x02010;mm lesions. The median total injection amount was 1 mL for 5&#x02013;10&#x02010;mm lesions and 3 mL for 11&#x02013;20&#x02010;mm lesions. The effective resection rate was 94% (95% CI, 85&#x02013;98) for 5&#x02013;10&#x02010;mm lesions and 84% (95% CI, 65&#x02013;94) for 11&#x02013;20&#x02010;mm lesions.</p><table-wrap position="float" id="deo270069-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Patient and non&#x02010;pedunculated lesion characteristics and treatment outcomes according to lesion size.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Lesions</th><th align="left" rowspan="1" colspan="1">
<p>5&#x02013;10 mm (<italic toggle="yes">n</italic>&#x000a0;= 66)</p>
<p>[95% confidence interval] (%)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>11&#x02013;20 mm (<italic toggle="yes">n</italic>&#x000a0;= 25)</p>
<p>[95% confidence interval] (%)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Location</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right colon</td><td align="char" rowspan="1" colspan="1">29 (43.9)</td><td align="char" rowspan="1" colspan="1">11 (44.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Left colon</td><td align="char" rowspan="1" colspan="1">29 (43.9)</td><td align="char" rowspan="1" colspan="1">9 (36.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">8 (12.0)</td><td align="char" rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Morphology</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;Is</td><td align="char" rowspan="1" colspan="1">46 (70.0)</td><td align="char" rowspan="1" colspan="1">16 (64.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0&#x02010;IIa</td><td align="char" rowspan="1" colspan="1">20 (30.3)</td><td align="char" rowspan="1" colspan="1">9 (36.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Experience, number of procedures</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02264;1000</td><td align="char" rowspan="1" colspan="1">23 (34.8)</td><td align="char" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1000&#x02013;2000</td><td align="char" rowspan="1" colspan="1">16 (24.2)</td><td align="char" rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2001&#x02013;5000</td><td align="char" rowspan="1" colspan="1">15 (22.7)</td><td align="char" rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;5000</td><td align="char" rowspan="1" colspan="1">12 (18.1)</td><td align="char" rowspan="1" colspan="1">12 (48.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of additional injections</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">66 (100)</td><td align="char" rowspan="1" colspan="1">23 (92.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td><td align="char" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total injection amount, mL</td><td align="char" rowspan="1" colspan="1">1 (0.2&#x02013;4)</td><td align="char" rowspan="1" colspan="1">3 (1&#x02013;14)</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">66 (100 [93.4&#x02013;100])</td><td align="char" rowspan="1" colspan="1">24 (96.0 [78.9&#x02013;100])</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete resection</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">62 (93.9 [85.0&#x02013;98.0])</td><td align="char" rowspan="1" colspan="1">21 (84.0 [64.7&#x02013;94.2])</td></tr><tr><td align="left" rowspan="1" colspan="1">Effective resection</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">62 (93.9 [85.0&#x02013;98.0])</td><td align="char" rowspan="1" colspan="1">21 (84.0 [64.7&#x02013;94.2])</td></tr></tbody></table><table-wrap-foot><fn id="deo270069-tbl5-note-0001"><p>Data are presented as <italic toggle="yes">n</italic> (%) or median (range).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo270069-sec-0190"><title>DISCUSSION</title><p>This is the first multicenter retrospective study to evaluate the feasibility of the novel submucosal injection material PuraLift in EMR. The results indicated that PuraLift is able to feasibly assist colorectal EMR.</p><p>The primary endpoint of this study was assessed by comprehensively evaluating en bloc complete resection with the lifting and maintenance of a mucosal lesion during endoscopic resection. A similar study using hyaluronic acid solution revealed a complete resection rate of 82.5% (33/40) and an en bloc resection rate of 92.5% (37/40).<xref rid="deo270069-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Other studies of EMR using the hyaluronic acid solution for lesions other than pedunculated lesions showed complete resection rates of 78.3%&#x02013;79.5% and en bloc resection rates of 93.3%&#x02013;96.7%.<xref rid="deo270069-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270069-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Although there were some minor differences compared with the present study, our results were considered generally favorable. In a similar study using a hyaluronic acid solution, additional injections were needed in only one patient, who required two additional injections.<xref rid="deo270069-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The results were similar to the present study, indicating that the bulge was generally maintained. There were no adverse events after EMR, such as bleeding or perforation. The data from this study suggest that this novel injection solution is useful in EMR because the complete resection and en bloc resection results were favorable, frequent additional injections were not required, and no adverse events associated with the solution occurred. Our data may contribute to the more widespread use of PuraLift by demonstrating its performance in a practical setting with endoscopists of varying levels of experience at community hospitals.</p><p>In the treatment of 11&#x02013;20&#x02010;mm lesions using a hyaluronic acid solution, a previous study revealed complete resection and en bloc resection rates of 72.2% and 85.1%, respectively.<xref rid="deo270069-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Underwater EMR showed a complete resection rate of 69.0% and en bloc resection rates of 84.6%&#x02013;89.0%.<xref rid="deo270069-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270069-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Although these data are not directly comparable because of the small number of patients in this study, the outcomes using PuraLift appear to be at least non&#x02010;inferior to other modalities. EMR using PuraLift seems to be a good option for moderate lesions of 11 to 20 mm. Given the cost of PuraLift, selective use of PuraLift in EMR procedures is necessary. As a next step in our research, we are planning a study to further investigate the efficacy of PuraLift specifically in larger lesions, particularly those suspected to be malignant, where en bloc resection is desired.</p><p>The main strength of this study is the participation of endoscopists with different levels of experience from community hospitals, indicating the generalizability of PuraLift. However, this study also had several limitations. First, this was a retrospective study, which may have introduced selection bias. A prospective study should be conducted to validate our results. Second, this study is a single&#x02010;arm study and does not include a comparison with other injection materials. A randomized controlled trial should be conducted. Third, the procedure time was not investigated because of the retrospective study design. Underwater EMR reportedly has a shorter procedure time than conventional EMR.<xref rid="deo270069-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> A shorter procedure time would naturally reduce patient discomfort; therefore, further investigation is desirable. We have several expectations regarding the use of this solution. PuraLift is a formulation similar in composition to PuraStat, which is a hemostatic agent used in endoscopic therapy. In addition, there are reports that PuraStat seems to promote ulcer healing.<xref rid="deo270069-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> We expect PuraLift to have similar effects. Further investigation is warranted to determine whether PuraLift can prevent perioperative bleeding and delayed bleeding and promote the healing of ulcers after endoscopic resection. Such effects may provide advantages over other injection solutions.</p></sec><sec id="deo270069-sec-0200"><title>CONCLUSION</title><p>Although direct comparison with other materials is required, PuraLift seems feasible as an injection material for EMR.</p></sec><sec sec-type="COI-statement" id="deo270069-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>Dr. Uraoka has received consulting and lecture fees from 3&#x02010;D Matrix Ltd. PuraLift was provided by 3&#x02010;D Matrix. Dr. Uraoka serves as Deputy Editor&#x02010;in&#x02010;Chief of <italic toggle="yes">DEN Open</italic>. Dr. Takeuchi serves as Associate Editor of <italic toggle="yes">DEN Open</italic>.</p></sec><sec id="deo270069-sec-0250"><title>ETHICS STATEMENT</title><p>Approval of the research protocol by an Institutional Reviewer Board: The study protocol was approved by the Gunma University Hospital Clinical Research Review Board (No. 2023&#x02013;033).</p></sec><sec id="deo270069-sec-0260"><title>PATIENT CONSENT STATEMENT</title><p>The requirement for informed consent from each patient was waived in this study.</p></sec><sec id="deo270069-sec-0270"><title>CLINICAL TRIAL REGISTRATION</title><p>N/A.</p></sec></body><back><ack id="deo270069-sec-0210"><title>ACKNOWLEDGMENTS</title><p>The authors also thank Angela Morben, DVM, ELS, from Edanz (<ext-link xlink:href="https://jp.edanz.com/ac" ext-link-type="uri">https://jp.edanz.com/ac</ext-link>) for editing a draft of this manuscript.</p></ack><sec sec-type="data-availability" id="deo270069-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="deo270069-bibl-0001"><title>REFERENCES</title><ref id="deo270069-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270069-cite-0001">
<string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fujii</surname>
<given-names>T</given-names>
</string-name>. <article-title>Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection</article-title>. <source>Drug Des Devel Ther</source>
<year>2009</year>; <volume>2</volume>: <fpage>131</fpage>&#x02013;<lpage>138</lpage>.</mixed-citation></ref><ref id="deo270069-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270069-cite-0002">
<string-name>
<surname>Jung</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>DI</given-names>
</string-name>. <article-title>Submucosal injection solutions for endoscopic mucosal resection and endoscopic submucosal dissection of gastrointestinal neoplasms</article-title>. <source>Gastrointest Interv</source>
<year>2013</year>; <volume>2</volume>: <fpage>73</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="deo270069-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270069-cite-0003">
<string-name>
<surname>Nakata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pioche</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kuribayashi</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The feasibility of a fully synthetic and self&#x02010;assembled peptide solution as submucosal injection material: A preliminary animal study</article-title>. <source>Scand J Gastroenterol</source>
<year>2021</year>; <volume>56</volume>: <fpage>984</fpage>&#x02013;<lpage>989</lpage>.<pub-id pub-id-type="pmid">34181504</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270069-cite-0004">
<string-name>
<surname>Kasuga</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakata</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>A novel submucosal injection material comprising a fully synthetic and self&#x02010;assembling peptide solution for endoscopic resection of large colorectal laterally spreading tumors</article-title>. <source>Endoscopy</source>
<year>2023</year>; <volume>55</volume>: <fpage>E621</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">37040891</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270069-cite-0005">
<string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujii</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Effectiveness of glycerol as a submucosal injection for EMR</article-title>. <source>Gastrointest Endosc</source>
<year>2005</year>; <volume>61</volume>: <fpage>736</fpage>&#x02013;<lpage>740</lpage>.<pub-id pub-id-type="pmid">15855984</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270069-cite-0006">
<string-name>
<surname>von Elm</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Egger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pocock</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Vandenbroucke</surname>
<given-names>JP</given-names>
</string-name>. <article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies</article-title>. <source>PLoS Med</source>
<year>2007</year>; <volume>4</volume>: <elocation-id>e296</elocation-id>.<pub-id pub-id-type="pmid">17941714</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270069-cite-0007">
<collab collab-type="authors">Endoscopic Classification Review Group</collab>
. <article-title>Update on the Paris classification of superficial neoplastic lesions in the digestive tract</article-title>. <source>Endoscopy</source>
<year>2005</year>; <volume>37</volume>: <fpage>570</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">15933932</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270069-cite-0008">
<string-name>
<surname>Sano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>SE</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Narrow&#x02010;band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team</article-title>. <source>Dig Endosc</source>
<year>2016</year>; <volume>28</volume>: <fpage>526</fpage>&#x02013;<lpage>533</lpage>.<pub-id pub-id-type="pmid">26927367</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270069-cite-0009">
<string-name>
<surname>Kudo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirota</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Colorectal tumours and pit pattern</article-title>. <source>J Clin Pathol</source>
<year>1994</year>; <volume>47</volume>: <fpage>880</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">7962600</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270069-cite-0010">
<string-name>
<surname>Kudo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamano</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kusaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</string-name>. <article-title>Diagnosis of colorectal tumorous lesions by magnifying endoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>1996</year>; <volume>44</volume>: <fpage>8</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">8836710</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0011"><label>11</label><mixed-citation publication-type="book" id="deo270069-cite-0011">
<collab collab-type="authors">Japanese Society for Cancer of the Colon and Rectum</collab>
, <source>Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma</source>, <edition>9th ed</edition>, <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanehara &#x00026; Co., Ltd</publisher-name>., <year>2018</year>.</mixed-citation></ref><ref id="deo270069-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270069-cite-0012">
<string-name>
<surname>Hirasaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kozu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Usefulness and safety of 0.4% sodium hyaluronate solution as a submucosal fluid &#x0201c;cushion&#x0201d; for endoscopic resection of colorectal mucosal neoplasms: A prospective multi&#x02010;center open&#x02010;label trial</article-title>. <source>BMC Gastroenterol</source>
<year>2009</year>; <volume>9</volume>: <fpage>1</fpage>.<pub-id pub-id-type="pmid">19128517</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270069-cite-0013">
<string-name>
<surname>Yoshida</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Naito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Inada</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic mucosal resection with 0.13% hyaluronic acid solution for colorectal polyps less than 20 mm: A randomized controlled trial</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2012</year>; <volume>27</volume>: <fpage>1377</fpage>&#x02013;<lpage>1383</lpage>.<pub-id pub-id-type="pmid">22554102</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270069-cite-0014">
<string-name>
<surname>Yoshida</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Naito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Inada</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Multicenter study of endoscopic mucosal resection using 0.13% hyaluronic acid solution of colorectal polyps less than 20 mm in size</article-title>. <source>Int J Colorectal Dis</source>
<year>2013</year>; <volume>28</volume>: <fpage>985</fpage>&#x02013;<lpage>991</lpage>.<pub-id pub-id-type="pmid">23271496</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270069-cite-0015">
<string-name>
<surname>Yamashina</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Akasaka</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Comparison of underwater vs. conventional endoscopic mucosal resection of intermediate&#x02010;size colorectal polyps</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>157</volume>: <fpage>451</fpage>&#x02013;<lpage>461</lpage>. e2.<pub-id pub-id-type="pmid">30981791</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270069-cite-0016">
<string-name>
<surname>Yen</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>FW</given-names>
</string-name>. <article-title>Underwater versus conventional endoscopic resection of nondiminutive nonpedunculated colorectal lesions: A prospective randomized controlled trial (with video)</article-title>. <source>Gastrointest Endosc</source>
<year>2020</year>; <volume>91</volume>: <fpage>643</fpage>&#x02013;<lpage>654</lpage>. e2.<pub-id pub-id-type="pmid">31628954</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270069-cite-0017">
<string-name>
<surname>Takeuchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shichijo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>R</given-names>
</string-name>. <article-title>Underwater endoscopic mucosal resection for colorectal lesions: Can it be an &#x0201c;underwater&#x0201d; revolution?</article-title>
<source>DEN Open</source>
<year>2022</year>; <volume>2</volume>: <elocation-id>e84</elocation-id>.<pub-id pub-id-type="pmid">35310727</pub-id>
</mixed-citation></ref><ref id="deo270069-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270069-cite-0018">
<string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ochiai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>A novel fully synthetic and self&#x02010;assembled peptide solution for endoscopic submucosal dissection&#x02010;induced ulcer in the stomach</article-title>. <source>Geastrointest Endosc</source>
<year>2016</year>; <volume>83</volume>: <fpage>1259</fpage>&#x02013;<lpage>1264</lpage>.</mixed-citation></ref></ref-list></back></article>